Abstract Introduction: AC plus a taxane is standard neoadjuvant therapy for high-risk early breast cancer, but AC may be unnecessary for pathologic complete response (pCR) in many patients. I-SPY2 is a phase 2 trial evaluating the use of 12 weeks of paclitaxel +/- an investigational drug followed by AC. Serial measurements of Functional Tumor Volume (FTV) by MRI, inter-regimen biopsies and pathology from surgery were used to determine the contribution of AC to reduction in FTV or pCR. Methods: 1187 patients enrolled between 2010-2022 had serial measurements of FTV. 150 patients received an inter-regimen biopsy. The primary endpoint of I-SPY2 is pCR. To determine how much AC contributed to the reduction in FTV, we calculated the total FTV decrease between pre-treatment and pre-surgery, and then computed the percentage (%) of the total FTV decrease seen after 12 weeks of paclitaxel regimen. We attributed pCRs observed among patients for whom taxane contributed 90% FTV reduction to AC and estimated the % patients achieving pCR from AC. For the subset with inter-regimen biopsy, we estimated the percentage achieving pCR from those patients with invasive cancer present at inter-regimen biopsy. Results: We found that by week 12 (end of taxane), 64% (763/1187) of patients had achieved ≥90% of their total FTV reduction. In 424/1187 (36%) patients had with taxane 90% response, and subsequent AC contributed to more than 10% of the total decrease in FTV. 90 pCRs (21%) were observed among these 424 patients or, overall, approximately 8% of patients achieved pCR from AC after taxane. Of note, 54/1187 (4.5%) patients had no response to a taxane regimen and had decreased in FTV due to AC alone. Of the 54/1187 responding to AC only, there were 11 pCRs. These results varied by response predictive subtypes as shown. When the subpopulation with post-paclitaxel biopsy was examined, 63/150 (42%) patients had invasive cancer at this timepoint. 47 patients received AC and 4/47 (8.5%) achieved a pCR after AC. 13/47 (28%) achieved RCB 0/1. Conclusions: Serial measurements of FTV identifies patients who had a favorable response to a taxane regimen. For those with a suboptimal response, AC provided some contribution to further decrease in tumor volume. However, only a small fraction achieved a complete response. Immune positive and HER2+ (non-luminal) had the biggest benefit, with only 3-6% of other subtypes achieved pCR. Thus, AC can be reserved for those patients with suboptimal response to the initial taxane therapy. I-SPY2.2 utilizes these data to avoid AC by allowing patients to proceed to surgery after serial MRI and biopsy predict a pCR at an early timepoint. While AC remains the standard of care in many neoadjuvant regimens, the low response rates seen in I-SPY2 suggests that more active regimens need to be developed for patients with disease resistant to a taxane based therapy. Citation Format: D. Yee, C. Yau, P. Norwood, D. M. Wolf, P. R. Pohlmann, N. Onishi, L. van 't Veer, A. Borowsky, W. F. Symmans, J. Perlmutter, J. C. Boughey, E. Price, W. Li, I-SPY Investigators, N. Hylton, L. J. Esserman. Quantifying the Contribution of Doxorubicin and Cyclophosphamide (AC) to Pathologic Response Following Neoadjuvant Taxane Therapy: Analysis of the I-SPY2 TRIAL abstract. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD6-09.
Yee et al. (Tue,) studied this question.